Current Research on Epilepsi Disease As Sunovion Epilepsy, Anticonvulsant Drugs And New Epilepsy Drugs
Epilepsy Synopsis
Epilepsy is a major neurological disorder
in which the brain activity becomes abnormal causing periods of unusual
behavior and sensations. It is also known as vanquix in Many regions. The disorder is noticeable in young children and young
adults.
Moreover, brain injuries which can trigger post-traumatic epilepsy (PTE) and
post-traumatic seizure (PTS) can fuel the demand in the epilepsy market.
what is epilepsi disease and anticonvulsant drugs in 2019?
The Global Epilepsy Market is projected to touch a valuation
of USD 9,509.2 million by
2023, exhibiting a CAGR of 8.20% over
the forecast period (2018-2023). High prevalence of anti epilepsy drugs among the
geriatric population and increase in cases of brain injuries caused by
accidents are major factors driving market growth of epilepsy medication.
Free Sample Here Developing economies in Africa offer a
prime opportunity for investment in the market. According to a report by the
World Health Organization (WHO) in 2017, nearly 80% of the patient population
with epilepsy live in middle- and low-income countries. Manufacturers of
epileptic drugs can capitalize on the opportunity to invest and establish
facilities to cater to the growing demand.
The high
susceptibility rate of attaining epilepsy pills among the elderly of levetiracetam drug class is projected to
drive market demand. As per the 2018 study in the Neuroepidemiology Journal,
the prevalence rate of drugs for epilepsy among individuals older than 60 was 7.7 per
1000.
Key players in the epilepsy market include,
·
Eisai
Co. Ltd. (Japan)
·
Novartis
AG (Switzerland)
·
Pfizer
Inc. (US)
·
GW
Pharmaceuticals PLC (UK)
·
Abbott
Laboratories (US)
·
UCB
SA (Belgium)
·
LivaNova
PLC (UK)
·
Medtronic
PLC (Ireland)
·
Johnson
& Johnson Services Inc. (US)
·
GlaxoSmithKline
PLC (UK)
·
and
NeuroPace Inc. (US).
this Research is also have Great Details of Other Content of https://healthcareresearchmarket09.blogspot.com/2019/10/epilepsy-market-making-money-moving.html
ReplyDelete